Monitoring Guidelines for Immunomodulatory Drug Therapy in Dermatology

The presentation discusses essential monitoring guidelines for dermatologists managing patients on immunomodulatory drugs, particularly biologics for conditions like psoriasis. Highlighting the importance of safety in administering these high-risk medications, the speaker outlines a case study of a patient requiring biologic treatment who presented with severe psoriasis and several concerning symptoms, necessitating comprehensive evaluation before initiating immunosuppression. Recommendations from the American Academy of Dermatology and the National Psoriasis Foundation guide initial screenings, including a Complete Blood Count (CBC) and Comprehensive Metabolic Panel (CMP) to assess liver and kidney function and identify potential infections or malignancies. The speaker emphasizes the significance of screening for Hepatitis B, Hepatitis C, and HIV, understanding that particular lab results may indicate a need for antiviral therapy before proceeding with biologic treatment. Additional screenings for latent tuberculosis (TB) and endemic mycoses are stressed, especially considering geographical risk factors. The guidelines advise caution with specific biologics associated with increased risks, such as anti-TNF agents and interleukin-17 inhibitors, particularly in susceptible populations. Maintaining current cancer screening for patients on biologics is also important for ensuring their safety. Overall, the presentation emphasizes a structured approach to patient monitoring to mitigate risks associated with immunomodulatory therapies in dermatology.